Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: The U.S. Food and Drug Administration questioned the differences in size and formulation of the patch used in trials and the to-be-marketed patch. The generic drugs maker, which received a “complete response letter” from the FDA, said it planned to work closely with the agency to address the questions. Such letters typically lay out FDA concerns that need to be addressed before a treatment is approved. Actavis’ contraceptive skin patch is designed to provide continuous delivery of the hormone norethindrone, a type of progestin, during a once-weekly, seven-day dosing regimen. Progestin, the synthetic form of female sex hormone progestogen, inhibits ovulation and thickens the layer of mucus at the cervix so sperm cannot enter the uterus. The treatment will compete with Johnson and Johnson’s Ortho Evra, an estrogen/progestin combination contraceptive patch. Estrogen is another female sex hormone. A progestin-only patch can be safer than combination patches as high levels of estrogen are often linked to blood clotting disorders and an increased risk of cancer. The company also filed on Tuesday an application to market the generic version of Merck & Co Inc’s NuvaRing, a estrogen/progestin combination hormonal contraceptive vaginal ring. Actavis said it may be the first applicant to file the application, which, if approved may entitle it to 180 days of generic market exclusivity. Shares of Dublin, Ireland-based Actavis were down 0.6 percent at $165.16 in early trading on the New York Stock Exchange on Tuesday.

Answer: FDA rejects Actavis' contraceptive patch, seeks more data.


Question: The Medicines and Healthcare products Regulatory Agency (MHRA) said it was investigating 14 fake or unlicensed products to treat COVID-19, the respiratory disease caused by the coronavirus. So far 3,605 Britons have died from the coronavirus, the latest data show, and experts have said deaths will continue to rise until the effect of recent lockdown measures filter through and slow the spread of the disease in the coming weeks. MHRA said it was investigating fake self-testing kits, miracle cures and so-called “antiviral misting sprays”. “Don’t be fooled by online offers for medical products to help prevent or treat COVID-19,” Lynda Scammell, MHRA enforcement official said. “There is no medicine licensed specifically to treat or prevent COVID-19, therefore any claiming to do so are not authorised and have not undergone regulatory approvals required for sale on the UK market.”  Scammell added that MHRA was working alongside law enforcement agencies to combat the spread of fake and unlicensed medical products.

Answer: Miracle cures? UK investigators go after fake coronavirus medicines.


Question: General health has improved worldwide, thanks to significant progress against infectious diseases such as HIV/AIDS and malaria in the past decade and gains in fighting maternal and child illnesses. But healthy life expectancy has not increased as much, so people are living more years with illness and disability, according to the analysis, published in The Lancet journal. “The world has made great progress in health, but now the challenge is to invest in finding more effective ways of preventing or treating the major causes of illness and disability,” said Theo Vos, a professor at the Institute of Health Metrics and Evaluation at the University of Washington who led the analysis. The study’s main findings were that global life expectancy at birth for both sexes rose by 6.2 years  — from 65.3 in 1990 to 71.5 in 2013. Healthy life expectancy at birth rose by 5.4 years — from 56.9 in 1990 to 62.3 in 2013. Healthy life expectancy takes into account both mortality and the impact of non-fatal conditions and chronic illnesses like heart and lung diseases, diabetes and serious injuries. Those detract from quality of life and impose heavy cost and resources burdens. For most of the 188 countries studied, changes in healthy life expectancy between 1990 and 2013 were “significant and positive”, the researchers said. But in many - among them Belize, Botswana and Syria - healthy life expectancy in 2013 was not much higher than in 1990. And in some, including South Africa, Paraguay, and Belarus, healthy life expectancy has dropped. In Lesotho and Swaziland, people born in 2013 could expect to live some 10 fewer healthy years than people born there 20 years earlier. The study also found stark differences between countries with the highest and lowest healthy life expectancies, and in the rates and direction of change. Nicaraguans and Cambodians have seen dramatic increases since 1990, of 14.7 and 13.9 years respectively. People in Botswana and Belize, however, saw declines of two and 1.3 years respectively. In 2013, Lesotho had the world’s lowest healthy life expectancy, at 42 years. Japan had the highest, at 73.4 years.

Answer:
Global life expectancy rises, but people live sicker for longer.